1.46
-0.02(-1.35%)
Currency In USD
| Previous Close | 1.48 |
| Open | 1.46 |
| Day High | 1.49 |
| Day Low | 1.45 |
| 52-Week High | 19.44 |
| 52-Week Low | 0.97 |
| Volume | 46,032 |
| Average Volume | 1.2M |
| Market Cap | 8.12M |
| PE | -0.05 |
| EPS | -27.2 |
| Moving Average 50 Days | 1.5 |
| Moving Average 200 Days | 4.36 |
| Change | -0.02 |
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
GlobeNewswire Inc.
Yesterday at 10:30 AM GMT
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from resp
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
GlobeNewswire Inc.
May 27, 2025 12:00 PM GMT
NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respi